- Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
More ▼
Key statistics
On Wednesday, Heron Therapeutics Inc (HRTX:NAQ) closed at 2.77, -29.52% below its 52-week high of 3.93, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.75 |
---|---|
High | 2.89 |
Low | 2.70 |
Bid | 2.77 |
Offer | 2.82 |
Previous close | 2.74 |
Average volume | 3.16m |
---|---|
Shares outstanding | 150.65m |
Free float | 149.60m |
P/E (TTM) | -- |
Market cap | 412.79m USD |
EPS (TTM) | -0.6156 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼